OverviewSuggest Edit

Urovant Sciences is a biopharmaceutical company focused on developing novel therapies for urologic conditions. The Company's lead therapeutic candidate is vibegron (RVT-901), an investigational oral β3-adrenergic agonist being developed for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.

TypePublic
Founded2016
HQIrvine, CA, US
Websiteurovant.com

Latest Updates

Employees (est.) (Mar 2019)39(+50%)
Job Openings26
Share Price (Apr 2021)$16.2
Cybersecurity ratingBMore

Key People/Management at Urovant Sciences

Jim Robinson

Jim Robinson

Chief Executive Officer, Director
Cornelia Haag-Molkenteller

Cornelia Haag-Molkenteller

EVP & Chief Medical Officer
Walt Johnston

Walt Johnston

EVP, Commercial
Ryan Card

Ryan Card

EVP & General Counsel
Kenton Stewart

Kenton Stewart

EVP, Market Access
Show more

Urovant Sciences Office Locations

Urovant Sciences has offices in Irvine and Basel
Irvine, CA, US (HQ)
5281 California Ave #100
Basel, CH
Viaduktstrasse 8
Show all (2)

Urovant Sciences Financials and Metrics

Urovant Sciences Revenue

USD

Net income (FY, 2020)

(146.7m)

Market capitalization (1-Apr-2021)

531.8m

Closing stock price (1-Apr-2021)

16.2

Cash (31-Mar-2020)

51.4m

EV

483.8m
Urovant Sciences's current market capitalization is $531.8 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

General and administrative expense

1.0m4.6m18.6m46.3m

R&D expense

26.0m32.4m92.2m92.4m

Operating expense total

27.1m37.0m110.8m138.7m

Interest expense

259.0k3.6m
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

General and administrative expense

334.1k3.5m3.7m4.9m5.5m7.4m16.7m

R&D expense

3.1m28.0m20.7m21.3m22.0m17.8m23.1m

Operating expense total

3.5m31.5m24.3m26.2m27.5m25.2m39.8m

Interest expense

309.0k513.0k581.0k1.4m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

4.8m7.2m85.4m51.4m

Prepaid Expenses

8.6k5.2m12.9m6.5m

Current Assets

4.8m12.4m98.5m58.3m

PP&E

509.6k923.0k1.2m
Quarterly
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

4.3m1.7m95.6m62.4m67.8m131.9m

Prepaid Expenses

5.9m11.8m15.1m8.4m8.8m10.2m

Current Assets

11.0m15.6m111.0m71.0m76.9m142.5m

PP&E

585.2k587.0k571.0k1.2m1.2m1.2m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(27.0m)(37.1m)(111.3m)(146.7m)

Depreciation and Amortization

12.4k180.0k246.0k

Accounts Payable

15.9k816.9k1.1m(336.0k)

Cash From Operating Activities

(25.3m)(34.1m)(109.0m)(102.1m)
Quarterly
USDQ1, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(3.6m)(31.3m)(55.9m)(82.4m)(28.5m)(54.2m)(95.5m)

Depreciation and Amortization

85.0k132.0k54.0k113.0k178.0k

Accounts Payable

114.2k4.2m3.8m2.9m834.0k(358.0k)463.0k

Cash From Operating Activities

(600.6k)(20.8m)(44.3m)(85.1m)(22.5m)(47.0m)(70.5m)
USDFY, 2017

Financial Leverage

1.2 x
Show all financial metrics

Urovant Sciences Operating Metrics

Q1, 2019

Phase III Patients Enrolled

1.4 k
Show all operating metrics

Urovant Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Urovant Sciences Online and Social Media Presence

Embed Graph

Urovant Sciences News and Updates

The American Urological Association and Urology Care Foundation Unveil New Urology Research Program Supported by $2 Million Donation from Urovant Sciences

BALTIMORE, April 1, 2021 /PRNewswire/ -- The American Urological Association (AUA) and Urology Care Foundation today announced the launch of a program aimed at fostering diversity and inclusion in urology research, supported by a generous $2 million donation from Urovant Sciences...

Sumitovant Biopharma Completes Acquisition of Urovant Sciences

NEW YORK, LONDON, IRVINE, CA & BASEL, SWITZERLAND, March 29, 2021 (GLOBE NEWSWIRE) -- Sumitovant Biopharma and Urovant Sciences (formerly Nasdaq: UROV) jointly announced today the completion of the merger in which Sumitovant has acquired all outstanding shares of Urovant Sciences.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Urovant Sciences Ltd. - UROV

NEW YORK, Nov. 13, 2020 /PRNewswire/-- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating Urovant Sciences Ltd. ("Urovant" or the "Company") (UROV) relating...

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Urovant Sciences Ltd. Buyout

WILMINGTON, Del., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Urovant Sciences Ltd. (“Urovant”) (NASDAQ GS: UROV) regarding possible breaches of fiduciary duties and other violations of law related to Urovant’s agreement to be acquired by Sumitov…

Urovant Sciences Blogs

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate

Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (vibegron) 75 mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart Rate crismangsat Mon, 09/13/2021 - 10:52 Urovant Scie…

Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the Virtual 2021 Annual Meeting of the American Urological Association

•     Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a virtual podium presentation •    Efficacy in patients with ‘dry’ overactive bladder, based on a post-hoc analysis of the pivotal EMPOWUR trial, will be the topic of a virtual poster presentation

Urovant Sciences to Present New Ambulatory Blood Pressure Data in Patients Dosed With GEMTESA® (vibegron) 75 mg for Overactive Bladder at the 2021 Annual Meeting of the American Urological Association

•    Data from the dedicated, stand-alone, ambulatory blood pressure trial will be the focus of a podium presentation •    Efficacy in patients with ‘dry’ overactive bladder, based on a post-hoc analysis of the pivotal EMPOWUR trial, will be the topic of a poster presentation   IRVINE, Calif.

Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer

Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer william.meady@… Wed, 08/11/2021 - 18:55 Urovant Sciences Appoints Betzy Estrada as Executive Vice President and Chief Human Resources Officer August 12, 2021 at 8:00 AM EDT …

Urovant Sciences Named One of the 2021 Best Places to Work in Orange County

IRVINE, Calif. & BASEL, Switzerland -- (BUSINESS WIRE) – July 6, 2021 -- Urovant Sciences, a wholly owned subsidiary of Sumitovant, has been named as one of the 2021 Best Places to Work in Orange County.  The awards program was created in 2009 and is a project of the Orange County Business Journ…

Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder

Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with Overactive Bladder jcong Tue, 06/29/2021 - 09:08 Urovant Sciences and Sunovion Pharmaceuticals Launch Primary Care Co-Promotion of GEMTESA® (vibegron) for Patients with O…
Show more

Urovant Sciences Frequently Asked Questions

  • When was Urovant Sciences founded?

    Urovant Sciences was founded in 2016.

  • Who are Urovant Sciences key executives?

    Urovant Sciences's key executives are Jim Robinson, Cornelia Haag-Molkenteller and Walt Johnston.

  • How many employees does Urovant Sciences have?

    Urovant Sciences has 39 employees.

  • Who are Urovant Sciences competitors?

    Competitors of Urovant Sciences include Novartis, Pfizer and Takeda Pharmaceutical.

  • Where is Urovant Sciences headquarters?

    Urovant Sciences headquarters is located at 5281 California Ave #100, Irvine.

  • Where are Urovant Sciences offices?

    Urovant Sciences has offices in Irvine and Basel.

  • How many offices does Urovant Sciences have?

    Urovant Sciences has 2 offices.